论文部分内容阅读
大肠杆菌(E.coli)是导致医院感染的一种重要条件致病菌。碳青霉烯类是临床治疗E.coli最为有效的抗生素之一。但是,临床上对该类药物的滥用情况严重,导致E.coli对碳青霉烯类抗生素的耐药率迅速上升。目前,全球对此类抗生素的耐药机制的研究十分紧迫。E.coli对碳青霉烯类的耐药机制主要包括:碳青霉烯酶的水解作用;外排转运系统的增强;青霉素结合蛋白(PBP)的改变;膜孔蛋白缺失合并高产Ampc酶或ESBLs。本文将从这四个方面阐述E.coli对碳青霉烯类抗生素的耐药机制。
Escherichia coli (E.coli) is an important opportunistic pathogen causing nosocomial infections. Carbapenems are one of the most effective antibiotics for the clinical treatment of E. coli. However, the serious abuse of such drugs clinically has led to a rapid increase in the rate of resistance to carbapenem in E. coli. At present, the global research on the mechanism of resistance to such antibiotics is very urgent. E. coli carbapenem resistance mechanisms include: carbapenemase hydrolysis; efflux transport system enhancement; penicillin-binding protein (PBP) changes; deletion of membrane pore protein with high yield Ampc enzyme or ESBLs. This article will explain the four aspects of E. coli carbapenem antibiotic resistance mechanism.